Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases

Lara C. Pullen, PhD  |  September 2, 2019

“Finally, the fact that the efficacy of rituximab was not optimal in almost a quarter of our patients may be explained by the incomplete administration of treatment and the information bias related to the mode of data collection, but also the neutralization of rituximab within immune complexes,” write the authors. “Indeed, studies have described a correlation between [human anti-chimeric antibodies] and an incomplete clinical response to rituximab.”


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum. 2015 Dec;45(3):334–340.
  2. Bayer G, Agier MS, Lioger B, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. Eur J Intern Med. 2019 Jul 3. pii: S0953-6205(19)30192-X. [Epub ahead of print]

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:rituximabrituximab-induced serum sicknessSerum Sickness

Related Articles
    Motortion Films / shutterstock.com

    A Look Back at Pirquet & Schick’s Influential Serum Sickness Study

    November 12, 2020

    In 1905, two pediatricians in Vienna, Austria, published Serum Sickness, a detailed 120-page monograph that was the first to carefully characterize the syndrome.1 The work would go on to become a classic, ultimately helping illuminate many important questions in immunology. Antitoxin Serum Treatments In the late 19th century, researchers were working to develop lifesaving antitoxins…

    A 52-Year-Old Lupus Paper Remains Important Today

    December 14, 2020

    Over 50 years ago, an article appeared in The New England Journal of Medicine: “Immunologic Factors and Clinical Activity in Systemic Lupus Erythema­tosus.”1 Written by a young postdoctoral fellow, Peter H. Schur, MD, and colleagues, the article synthesized important work in the field at the time. What follows is a discussion of the historical context…

    How a Nuclear Molecule Alarms the Immune System

    August 1, 2011

    The role of HMGB1 in the pathogenesis of lupus nephritis

    Doest Rheumatoid Arthritis Take a Toll?

    November 15, 2013

    Exploring the Toll background

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences